Roberts Capital Advisors’s Gilead Sciences GILD Stock Holding History

Roberts Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,920	Closed	-$327K	–	81
2025 Q1	$327K	Hold	2,920	–	–	0.29%	82
2024 Q4	$270K	Hold	2,920	–	–	0.23%	78
2024 Q3	$245K	Hold	2,920	–	–	0.21%	85
2024 Q2	$214K	Hold	2,920	–	–	0.21%	86
2024 Q1	$214K	Buy	+2,920	New	+$225K	0.21%	86
2022 Q3	$193K	Hold	3,131	–	–	0.28%	83
2022 Q2	$194K	Hold	3,131	–	–	0.27%	83
2022 Q1	$186K	Hold	3,131	–	–	0.19%	94
2021 Q4	$227K	Buy	+3,131	New	+$216K	0.21%	92

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Roberts Capital Advisors's GILD Position: Q2 2025 in Review

Roberts Capital Advisors sold out of Gilead Sciences (GILD) in Q2 2025, closing a stake of 2,920 shares — an estimated $327K sold.

Roberts Capital Advisors first reported a position in GILD in Q4 2021 and held it in 9 quarters. The position peaked at $327K in Q1 2025. 2,024 funds tracked by Wall St. Rank hold GILD as of Q2 2025.

Roberts Capital Advisors reported no remaining Gilead Sciences position as of Q2 2025 after selling out during the quarter.
Roberts Capital Advisors sold 2,920 Gilead Sciences shares in Q2 2025, an estimated $327K.
Roberts Capital Advisors first reported a position in Gilead Sciences in Q4 2021 and held it in 9 quarters.
Roberts Capital Advisors's Gilead Sciences position peaked at $327K in Q1 2025.
2,024 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2025.

Based on Roberts Capital Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.